RP Bio Q1 Net Profit KRW 2.6B, Performance Improves Despite Credit Downgrade
-
Revenue KRW 35.1B (vs Q1 2025 KRW 34.0B, +3.3%)
-
Operating profit KRW 2.4B (increase YoY, exact figure undisclosed)
-
Net profit KRW 2.6B (vs Q1 2025 KRW 1.7B, +54%)
-
Capital procurement ratio 5.26% (improved from 8.22% at year-end, net debt decreased)
-
Credit rating: BB by iCreable (May 2025) vs BBB- in prior year
-
Maintains >60% market share in OTC soft capsules
-
No disclosure of share buyback/cancellation or dividends
KOSDAQ Filing Information
-
Filing: Quarterly Report (2026.03)
-
Company: RPbio (314140)
-
Submission: RPbio Inc.
-
Receipt: 05-15-2026